Ewing Sarcoma Pipeline Review, H1 2018 - Therapeutics Development Analyzed, Key Companies Involved and Drug Profiles Covered - ResearchAndMarkets.com

June 5, 2018

DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Ewing Sarcoma - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 15, 5, 1, 23 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.

Key Topics Covered

Introduction Ewing Sarcoma - Overview Ewing Sarcoma - Therapeutics Development Ewing Sarcoma - Therapeutics Assessment Ewing Sarcoma - Companies Involved in Therapeutics Development Ewing Sarcoma - Drug Profiles Ewing Sarcoma - Dormant Projects Ewing Sarcoma - Discontinued Products Ewing Sarcoma - Product Development Milestones Appendix

Companies Mentioned

Amgen Inc AntiCancer Inc Astellas Pharma Inc Bristol-Myers Squibb Co Cebiotex SL Celgene Corp Celldex Therapeutics Inc Cellectar Biosciences Inc Eisai Co Ltd EntreChem SL Exelixis Inc Gradalis Inc Incyte Corp Ipsen

For more information about this report visit https://www.researchandmarkets.com/research/8ndvpn/ewing_sarcoma?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006553/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 02:31 PM/DISC: 06/05/2018 02:31 PM


Update hourly